N
nContact Surgical
Medical device company that develops devices supporting endoscopic treatments for heart rhythm disorders
About nContact Surgical
nContact Surgical, founded in 2005 by Sidney Fleischman and Jim Whayne, specialized in developing medical devices for less invasive cardiac ablation procedures to treat atrial fibrillation (AFib). Initially named nContact Surgical, the company rebranded to nContact Inc. in 2011 to reflect its focus on less invasive, endoscopic approaches. The firm operated out of Morrisville, North Carolina, and focused on the market of patients with heart rhythm disorders, particularly those with enlarged atria who lacked reliable treatment alternatives.
The company's business revolved around the design, manufacturing, and sale of its cardiac ablation technology to healthcare facilities. A key part of its strategy involved fostering collaboration between cardiac surgeons and electrophysiologists. nContact's technology facilitates a multidisciplinary therapy known as the Convergent procedure, where a surgeon performs a closed-chest epicardial ablation, which is then complemented by an electrophysiologist's endocardial catheter ablation. This approach aimed to provide a more comprehensive treatment for persistent AFib. Throughout its history, nContact raised significant capital, securing a total of $67.7 million over eight funding rounds from investors including Harbert Venture Partners, ZMV Associates, and Hercules Capital.
nContact's flagship product was the EPi-Sense Guided Coagulation System with VisiTrax. This system was designed for the coagulation of cardiac tissue using radiofrequency (RF) energy. Its unique features included the integration of suction to ensure stable contact with the beating heart, perfusion, and RF energy delivery. The EPi-Sense device also incorporated embedded sensors to provide real-time electrical feedback, allowing physicians to map the heart and verify the completeness of lesions during the procedure. This technology received CE Mark approval in Europe for treating atrial fibrillation and atrial flutter and was cleared by the FDA in the U.S. for endoscopic coagulation of cardiac tissue. A significant milestone was the initiation of the CONVERGE IDE clinical trial, a head-to-head study evaluating the Convergent Procedure against catheter ablation for persistent AFib. In October 2015, nContact was acquired by AtriCure, Inc. for approximately $99 million in a cash-and-stock deal, with potential for an additional $50 million in milestone payments. The acquisition was a strategic move for AtriCure to expand its presence and product offerings in the AFib market.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Employees
- 13
- Open positions
- None listed
- Dealroom signal
- 56.6/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Human Resources, Biotechnology, Surgery, Cardiology and cardiovascular, Non-Invasive medical devices and treatments, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Oct 2015 | $149M | $149M | AtriCure | — |
| DEBTDebt | Nov 2014 | $20M | — | Hercules Capital | — |
Growth signals
Latest recorded traffic for nContact Surgical is 230 monthly website visits. nContact Surgical's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
nContact Surgical in the Morrisville ecosystem
The nContact Surgical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Intersouth Partners
Finistere Ventures- MCMassey Burch Capital Corporation
Series B and later3 investors entered at this stage
Harbert Growth Partners- ZAZMV Associates
Hercules Capital
Other known investors1 additional known investor
AtriCure
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about nContact Surgical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See nContact Surgical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







